Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Soluble Nucleoporin, sPOM121, promotes prostate cancer progression and immune evasion through direct promoter regulation at active transcriptional hubs [RNA-seq]

ABSTRACT: The role of nucleoplasmic residing nucleoporins (NUPs) in solid tumors, including prostate cancer, remain unknown. Here we uncover the clinical relevance and mechanistic role of the off-pore NUP soluble POM121 (sPOM121) as a critical transcriptional regulator enhancing lethal prostate cancer aggressiveness. Mechanistically we found that sPOM121, through its C-terminal domain associates with the chromatin remodeler SMARCA5 at nuclear condensates facilitating transcriptional activation at promoter sites. Indeed, sPOM121 through this mechanism regulates a discrete oncogenic gene network, including B-catenin, leading to tumor progression and immune evasion in prostate cancer. Notably, targeting the sPOM121-B-catenin axis in patient derived pre-clinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances anti-tumor immunity. Together, our findings reveal previously unknown actionable transcriptional rewiring functions of the nucleoplasmic residing NUP, sPOM121, in solid tumors, promoting lethal prostate cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE281298 | GEO | 2025/07/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Soluble Nucleoporin, sPOM121, promotes prostate cancer progression and immune evasion through direct promoter regulation at active transcriptional hubs [ATAC-seq]

Project description:The role of nucleoplasmic residing nucleoporins (NUPs) in solid tumors, including prostate cancer, remain unknown. Here we uncover the clinical relevance and mechanistic role of the off-pore NUP soluble POM121 (sPOM121) as a critical transcriptional regulator enhancing lethal prostate cancer aggressiveness. Mechanistically we found that sPOM121, through its C-terminal domain associates with the chromatin remodeler SMARCA5 at nuclear condensates facilitating transcriptional activation at promoter sites. Indeed, sPOM121 through this mechanism regulates a discrete oncogenic gene network, including B-catenin, leading to tumor progression and immune evasion in prostate cancer. Notably, targeting the sPOM121-B-catenin axis in patient derived pre-clinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances anti-tumor immunity. Together, our findings reveal previously unknown actionable transcriptional rewiring functions of the nucleoplasmic residing NUP, sPOM121, in solid tumors, promoting lethal prostate cancer.

2025-07-22 | GSE281296 | GEO

Soluble Nucleoporin, sPOM121, promotes prostate cancer progression and immune evasion through direct promoter regulation at active transcriptional hubs [ChIP-seq]

2025-07-22 | GSE281297 | GEO

Role of MITF in advanced lethal prostate cancer

Project description:Great efforts have been made to identify key molecular aberrations that sustain growth and confer resistance to androgen deprivation therapy (ADT) in advanced prostate cancer (PC), and yet PC remains a lethal disease. Recent years have witnessed the discovery of several master regulator transcription factors that enhance lethal PC aggressiveness and provide actionable targets that may improve patient survival. Here we explore the role of the microphthalmia transcription factor (MITF) in lethal prostate cancer. To identify the mechanisms through which MITF mododulates prostate cancer aggressiveness, we knock-down MITF in three prostate cancer cell lines to identify the MITF regulated effector gene network contributing to lethal prostate cancer. Methods: We compared global transcription of three prostate cancer cell lines transduced with a siRNA control and 2 siRNAs targetting MITF by RNAseq. Results: RNA-seq of MITF knockdown prostate cancer cells uncovered a trasncriptional network of MITF regulated genes Conclusions: MITF regulates a discrette gene network that contributes to prostate cancer aggressiveness

2023-12-22 | GSE133977 | GEO

Human Prostate Tumor Subtypes

Project description:Prostate cancer is the Prostate cancer is the most prevalent cancer in men. However, the majority of prostate cancers diagnosed today are indolent with 14% of patients diagnosed with lethal prostate cancer. It is of great importance to determine the molecular features that are involved in the aggressiveness of prostate cancers. To this end, we found that through SWATH-MS proteomics analyses of 108 well-preserved frozen prostate tissues of various disease states, tmost prevalent cancer in men. However, the majority of prostate cancers diagnosed today are indolent with 14% of patients diagnosed with lethal prostate cancer. It is of great importance to determine the molecular features that are involved in the aggressiveness of prostate cancers. To this end, we deployed SWATH-MS proteomics analyses of 108 well-preserved frozen prostate tissues of various disease states.

2022-02-28 | PXD002306 | Pride

Transcriptomics biomarkers in prostate cancer

Project description:Prostate cancer (PCa) is the number one cancer in men. It represents a challenge for its management due to its very high incidence but low risk of lethal cancer. Over-diagnosis and over-treatment are therefore two pitfalls. The PSA (Prostate Specific Antigen) assay used for early diagnosis and clinical or molecular prognostic factors are not sufficiently reliable to predict the evolution of the cancer and its lethal or non-lethal character. Although PCa is most often detected at a localised stage, there are almost 30% of metastatic or locally advanced forms for which treatments can slow down the evolution but cannot be curative. With the use of high-throughput technological tools such as transcriptomics , it is becoming possible to define molecular signatures and identify predictive biomarkers of tumour aggressiveness . Here, we have analyzed 137 samples.

2022-05-18 | GSE200879 | GEO

Single-cell RNA Sequencing Demonstrates Inter-Patient Heterogeneity and Altered Tumor Microenvironment in Invasive and Intraductal Cribriform Prostate Cancer

Project description:ICC and IDC are aggressive histological subtypes of prostate cancer that are associated with progression to lethal disease. To delineate cancer cell intrinsic as well as tumor microenvironmental factors that contribute to ICC/IDC aggressiveness, this study examined paired ICC/IDC-enriched and benign-enriched prostate samples obtained from radical prostatectomy (RP) by scRNAseq, TCR sequencing and histology. ICC/IDC cancer cells had robust inter-patient heterogeneity but upregulated similar pathways (MYC and TNF via NFĸB) and targets with potential for therapeutic intervention (PSMA and B7-H3). ICC/IDC was associated with increased neovasculature, and cancer foci were densely circumscribed by immunosuppressive CAF likely derived from APOD+ peri-epithelial fibroblast progenitors. The ICC/IDC TME had fewer and more dysfunctional T cells and increased M2 polarization of two macrophage subtypes compared to benign prostate. These findings support that ICC/IDC are hallmarked by several aggressive features that likely contribute to their association with lethal prostate cancer.

2022-09-22 | GSE185344 | GEO

RAD21 promotes oncogenesis and lethal progression of prostate cancer

Project description:Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this study, we assessed in patients which genes on chromosome 8q, one of the most frequently gained chromosome arms in prostate tumors, were most strongly associated with long-term risk of cancer progression to metastases and death from prostate cancer (lethal disease) in 403 patients and found the strongest candidate was cohesin subunit gene, RAD21, with an odds ratio of 3.7 (95% CI 1.8, 7.6) comparing the highest vs. lowest tertiles of mRNA expression and adjusting for overall aneuploidy burden and Gleason score, both strong prognostic factors in primary prostate cancer. Studying prostate cancer driven by the TMPRSS2-ERG oncogenic fusion, found in about half of all prostate tumors, we found that increased RAD21 alleviated toxic oncogenic stress and DNA damage caused by oncogene expression. Data from both organoids and patients indicate that increased RAD21 thereby enables aggressive tumors to sustain tumor proliferation, and more broadly suggests one path through which tumors benefit from aneuploidy.

2024-07-26 | GSE265776 | GEO

B-catenin downregulates Dicer to promote ovarian cancer metastasis

Project description:Ovarian cancer is a nearly uniform lethal disease and its highly aggressive metastatic phenotype portends a poor prognosis. Lack of a well-controlled, relevant experimental model has been a major obstacle to identifying key molecules causing metastasis. Here we describe the creation of a new isogenic model of spontaneous human ovarian cancer metastasis exhibiting opposite phenotypes - highly metastatic (HM) and non-metastatic (NM) - both in vitro and in vivo. HM was unique in its ability to metastasize consistently to the peritoneum, mimicking the major dissemination route of human ovarian cancer. In contrast, NM failed to form detectable metastases although it was equally tumorigenic. Using comparative label-free quantitative LC-MS/MS, we identified b-catenin which we demonstrated for the first time a direct role in the pathogenesis of ovarian cancer metastasis. Our studies also revealed a previously unrecognized role of b-catenin in the downregulation of multiple microRNAs (miRNAs) through attenuating miRNA biogenesis by targeting Dicer, a key component of the microRNA processing machinery. One such downregulated miRNAs was miR-29s involved in epithelial-to-mesenchymal transition and subsequent stem cell traits. Silencing b-catenin or overexpressing Dicer or miR-29 mimics in HM significantly reduced the ability of these cells to migrate. B-catenin knockdown cells also failed to metastasize in an orthotopic model of ovarian cancer. Meta-analysis revealed an increase in CTNNB1 and a decrease in DICER1 expression levels in the high-risk group. These results uncover b-catenin as a critical player in promoting ovarian cancer aggressiveness and a new mechanism linking between b-catenin and miRNA downregulation underlying this process.

2017-07-03 | PXD006327 | Pride

Inhibition of Androgen Receptor and β-catenin activity in prostate cancer

Project description:Androgen receptor (AR) is the major therapeutic target in aggressive prostate cancer. However, targeting AR alone can result in drug resistance and disease recurrence. Therefore, simultaneous targeting of multiple pathways could in principle be an effective new approach to treating prostate cancer. Here we provide proof-of-concept that a small molecule inhibitor of nuclear β-catenin activity (called C3) can inhibit both the AR and β-catenin signaling pathways that are often misregulated in prostate cancer. Treatment with C3 ablated prostate cancer cell growth by disruption of both β-catenin/TCF and β-catenin/AR protein interaction, reflecting the fact that TCF and AR have overlapping binding sites on β-catenin. Given that AR interacts with, and is transcriptionally regulated by β-catenin, C3 treatment also resulted in decreased occupancy of β-catenin on the AR promoter and diminished AR and AR/β-catenin target gene expression. Interestingly, C3 treatment resulted in decreased AR binding to target genes accompanied by decreased recruitment of an AR and β-catenin cofactor, CARM1, providing new insight into the unrecognized function of β-catenin in prostate cancer. Importantly, C3 inhibited tumor growth in an in vivo xenograft model, and blocked renewal of bicalutamide-resistant sphere forming cells, indicating the therapeutic potential of this approach. Compare and contrast the expression profile of prostate cancer cells treated with a Wnt inhibitor (C3) with respect to β-catenin and AR knockdown (all samples in duplicates).

2014-01-23 | E-GEOD-49295 | biostudies-arrayexpress

MicroRNA profiling in primary prostate cancer

Project description:Deregulated expression of miRNAs contributes to prostate cancer progression. This study is aimed to identify which miRNA(S) is (are) asociated with prostate cancer aggressiveness. Prostate cancer tissues and matched adjacent normal tissue were used to isolate total RNA. miRNA expressions were analyzed by miRNA Microarray assay.

2011-12-10 | E-GEOD-34310 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data